Exact Sciences recently announced its latest financial report, which showed revenue of $454.5 million and  934,000 completed Cologuard tests during last year, an increase of 71 percent and 64 percent, respectively, from 2017.

“The Exact Sciences team made tremendous progress in 2018, and we look forward to helping more people get screened for colorectal cancer in 2019 through our partnership with Pfizer,” Exact Sciences CEO Kevin Conroy said in a statement. “Our team continues working hard to advance our pipeline of liquid biopsy tests to deliver additional life-changing innovations in early cancer detection.”

According to a release, nearly 15,000 healthcare providers ordered their first Cologuard test during the fourth quarter, and approximately 147,000 total providers have ordered since the test was launched.

Exact Sciences hopes to make $710 million to $730 million in 2019.